New insights into the pathophysiology and treatment of migraine;Neues zu pathophysiologie und therapie der migräne

Psycho

Volumn 28, Issue 5, 2002, Pages 251-259

  Limmroth, Volker ^a   Diener, Hans Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; DOMPERIDONE; ELETRIPTAN; ERGO SANOL; ERGOTAMINE; ERGOTAMINE TARTRATE; FROVATRIPTAN; IBUPROFEN; LYSINE ACETYLSALICYLATE; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; PARACETAMOL; RIZATRIPTAN; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; DRUG CHOICE; HUMAN; MIGRAINE; MIGREXA; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

EID: 17344376923     PISSN: 03407845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Brainstem activation specific to migraine headache
2. Prophylaxis of migraine: A comparison between naproxen sodium and pizotifen
3. Comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis
4. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model
5. The safety and tolerability of sumatriptan: An overview
6. Low-dose aspirin for migraine prophylaxis
7. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks
8. Perfusion-weighted imaging defects during spontaneous migrainous aura
9. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: An open pilot study
10. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (cafergot((R)) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison
11. Flunarizine for migraine prophylaxis
12. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study
13. Acetylsalicylic acid in migraine prophylaxis: A double blind study in comparison with metoprolol
14. Advances in the pharmacological treatment of migraine
15. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells
16. Neuropeptides in migraine and cluster headache
17. Neuropeptides in headache
18. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials
19. Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan
20. The trigeminovascular system and migraine: Studies characterizing cerebravascular and neuropeptide changes seen in humans and cats
21. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat
22. Selective seratonin 1F (5HT(1F)) receptor agonist LY334370 for acute migraine: A randomised controlled trial
23. Ineffectiveness of neurokinin-1 antagonist in acute migraine: Crossover study
24. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine
25. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine
26. Mechanisms of migraine aura revealed by functional MRI in human visual cortex
27. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study
28. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine
29. A gene for familial hemiplegic migraine maps to chromosome 19
30. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine
31. Divalproex sodium in migraine prophylaxis: A dose-controlled study
32. Lamotrigine in the prophylactic treatment of migraine aura - A pilot study
33. Changes of cerebral blood flow velocity after treatment with sumatriptan or placebo and its implication in the pathophysiology of migraine
34. Acetylsalicylic acid in the treatment of migraine and other headache - A historical and current overview
35. Lysineacetylsalicylic acid in acute migraine attacks
36. The Prevention of Migraine: A critical review with special emphasis on β-blockers
37. A new in vivo rat model for CGRP release following the activation of the trigeminal vascular system
38. Efficacy of gabapentin in migraine prophylaxis
39. Migraine prophylaxis with divalproex
40. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks
41. Experimental cranial pain elicited by capsaicin: A PET study
42. Acupuncture for recurrent headaches: A systematic review of randomized controlled trials
43. Basic mechanisms in vascular headache
44. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
45. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study
46. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4
47. No acute antimigraine efficiacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials
48. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura
49. Topiramate in migraine prevention: A double-blind, placebo-controlled study
50. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine
51. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
52. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo
53. Brain stem activation in spontaneous human migraine attacks